Addressing Circulatory Dysfunction
The pathophysiology of decompensated cirrhosis is defined by profound circulatory dysfunction. Systemic vasodilation leads to effective hypovolemia, triggering neurohormonal systems that ultimately cause renal failure and life-threatening complications. Our clinical approach focuses on safely reversing this vasodilation to restore hemodynamic stability.
Subcutaneous Innovation
Rallidae Therapeutics is advancing a first-in-class subcutaneous V1aR partial agonist designed to address the foundational circulatory dysfunction in decompensated cirrhosis. Unlike traditional full agonists that may lead to excessive vasoconstriction and safety concerns, our approach utilizes a partial agonist mechanism to safely reverse vasodilation. By stabilizing hemodynamics through a convenient subcutaneous delivery, we aim to prevent the severe complications of cirrhosis while improving patient compliance and standard of care.
Clinical Pipeline
Preclinical Research & V1aR Selection
Phase I: Safety and Initial Efficacy
Phase II: Clinical Proof of Concept
Baseline Establishment
Q3 2025 Milestones
Expected 2026 Launch